Analyst Conference Summary

biotechnology

conference date: October 29, 2026 @ 5:30 AM Pacific Time
for quarter ending: September 30, 2026 (third quarter, Q3)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was $ billion, up % sequentially from $1.29 billion, and up % from $ million year-earlier.

Net income was $ million, down % sequentially from $164 million, and up from negative $ million year-earlier.

Diluted EPS was $, down % sequentially from $1.21, and up from negative $ year-earlier.

Guidance:

Conference Highlights:

Yvonne Greenstreet, CEO of Alnylam, said: ""

Alnylam will present initial results from the Phase 1 trial of ALN-HTT02 in patients with Huntington's disease at EHDN Clinical Research Congress on October 23, 2026.

Alnylam expects Phase 1 results in 2H 2026 for ALN-2232 for weight management.

Net revenue from collaborations was $ million, down from $ million year-earlier. Royalty revenue was $ million, up from $ million year-earlier.

Non-GAAP net income $ million, down % sequentially from $252 million, and up from $ million year-earlier. EPS diluted $, down % sequentially from $1.84, and up from $ year-earlier.

Cash and equivalents balance at the end of the quarter was $ billion, up sequentially from $3.3 billion. Net cash provided by operating activities was $ million. Debt was $1 billion.

See also Alnylam pipeline. In late 2026 had 25 clinical programs including many in late stages.

Operating expenses of $ billion consisted of: $ million for cost of goods sold; $ million for research and development; and $ million for general and administrative expense; $0 million cost of collaboration. Operating income $ million. Interest & other expense $ million. $ million income tax.

Q&A Selective Summary:

OpenIcon Alnylam page

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: